The estimated Net Worth of Chau Quang Khuong is at least $187 Millón dollars as of 2 November 2020. Mr. Khuong owns over 733,333 units of Nextcure Inc stock worth over $1,465,172 and over the last 10 years he sold NXTC stock worth over $185,167,236. In addition, he makes $245,194 as Independent Director at Nextcure Inc.
Sign up
Mr. Khuong NXTC stock SEC Form 4 insiders trading
Chau has made over 17 trades of the Nextcure Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 733,333 units of NXTC stock worth $10,999,995 on 2 November 2020.
The largest trade he's ever made was buying 777,500 units of Nextcure Inc stock on 28 June 2018 worth over $2,993,375. On average, Chau trades about 85,014 units every 34 days since 2014. As of 2 November 2020 he still owns at least 1,031,811 units of Nextcure Inc stock.
You can see the complete history of Mr. Khuong stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Chau Khuong biography
Chau Q. Khuong serves as Independent Director of the Company. He has served as a Private Equity Partner at OrbiMed Advisors LLC, a venture capital and asset management firm, since 2003. Mr. Khuong currently serves as a director of several publicly traded life sciences companies, including BELLUS Health Inc. since December 2018, Synlogic, Inc. since February 2016, Inspire Medical Systems, Inc. since May 2014 and Aerpio Pharmaceuticals, Inc. since April 2014, and previously served as a director of publicly traded biopharmaceutical companies Nabriva Therapeutics plc (formerly Nabriva Therapeutics AG) from April 2015 to August 2017 and Otonomy, Inc. from August 2013 to July 2016 and as chairman of the board of directors of biopharmaceutical company Pieris Pharmaceuticals, Inc. from December 2014 to November 2017. Mr. Khuong has also served on the board of directors for several privately held companies. Mr. Khuong received a B.S. in molecular biology with concentration in biotechnology and a M.P.H. with concentration in infectious diseases from Yale University.
What is the salary of Chau Khuong?
As the Independent Director of Nextcure Inc, the total compensation of Chau Khuong at Nextcure Inc is $245,194. There are 10 executives at Nextcure Inc getting paid more, with Steven Cobourn having the highest compensation of $993,341.
How old is Chau Khuong?
Chau Khuong is 44, he's been the Independent Director of Nextcure Inc since 2015. There are 21 older and no younger executives at Nextcure Inc. The oldest executive at Nextcure Inc is David Kabakoff, 72, who is the Independent Chairman of the Board.
What's Chau Khuong's mailing address?
Chau's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.
Insiders trading at Nextcure Inc
Over the last 5 years, insiders at Nextcure Inc have traded over $0 worth of Nextcure Inc stock and bought 1,475,000 units worth $25,387,500 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Chau Quang Khuong y Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of $233,653. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth $48,195.
What does Nextcure Inc do?
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
What does Nextcure Inc's logo look like?
Complete history of Mr. Khuong stock trades at Otonomy Inc, Pieris Pharmaceuticals Inc, Synlogic Inc, Inspire Medical Systems Inc, Aerpio Pharmaceuticals Inc, Nextcure Inc, Fusion Pharmaceuticals y Galecto
Nextcure Inc executives and stock owners
Nextcure Inc executives and other stock owners filed with the SEC include:
-
Steven Cobourn,
Chief Financial Officer -
Michael S. Richman MSBA,
Co-Founder, CEO, Pres & Director -
Michael S. Richman,
Co-Founder, CEO, Pres & Director -
Michael Richman,
President, Chief Executive Officer, Director -
Sol Langermann,
Chief Scientific Officer -
Dr. Solomon Langermann Ph.D.,
Chief Scientific Officer -
David Kabakoff,
Independent Chairman of the Board -
Stephen Webster,
Independent Director -
Briggs Morrison,
Independent Director -
Timothy Mayer,
Chief Operating Officer -
Chau Khuong,
Independent Director -
Elaine Jones,
Independent Director -
Stella Xu,
Independent Director -
John Houston,
Director -
Garry Nicholson,
Independent Director -
Linda Liu,
Senior Vice President - Research -
James Bingham,
Chief Development Officer -
Sourav Kundu Ph.D.,
Sr. VP of Devel. & Manufacturing -
Dr. Han Myint FACP, M.D.,
Chief Medical Officer -
Dr. Timothy Mayer Ph.D.,
Chief Operating Officer -
Steven P. Cobourn CPA, CPA,
Chief Financial Officer -
Dr. Lieping Chen M.D., Ph.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Kevin N. Heller,
Chief Medical Officer -
Venture Partners Ix, L.P.So...,
-
Advisors Llc Orbi Med Capit...,
-
X L.P.Canaan Partners X Llc...,
-
Timothy M Shannon,
Director -
Judith Li,
Director -
Anne Elizabeth Borgman,
-
Ellen Feigal,
-
Sourav Kundu,
Sr VP, Dev. & Mfg. -
Han Myint,
Chief Medical Officer -
Kevin G. Shaw,
Sr VP, General Counsel